CNBC March 25, 2025
Novo Nordisk is taking aim at its rival, Eli Lilly, with a new obesity drug deal.
On Monday, the Danish drugmaker said it had agreed to pay up to $2 billion for the rights to an experimental drug from the Chinese pharmaceutical company United Laboratories International. The injectable treatment – UBT251 – is in early development to treat obesity, Type 2 diabetes and other conditions, so it could take several years before it enters any market.
Novo Nordisk will pay $200 million up front and milestone payments of up to $1.8 billion, along with tiered royalties. The deal gives the company exclusive rights to develop, manufacture and commercialize the drug globally, but not in the Chinese mainland, Hong...
Today's Sponsors
Today's Sponsor